Skip to main content

Refine your results

Filters
Date
Displaying 81 - 100 of 202

Statement of Chair Lina M. Khan at the September Open Commission Meeting on Brand Drug Manufacturers’ Improper Listing of Patents in the Orange Book

Date
By
Lina M. Khan, Former Chair and Commissioner
Related Releases
FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’

Statement of Chair Lina M. Khan Joined By Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro Bedoya In the Matter of Amgen, Inc. and Horizon Therapeutics plc

Date
By
Lina M. Khan, Former Chair and Commissioner;
Alvaro Bedoya, Former Commissioner;
Rebecca Kelly Slaughter, Former Commissioner
Related Releases
Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition

Statement of Chair Lina M. Khan, Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya, in the Matter of EQT Corporation

In the Matter of EQT Corporation
Date
Matter Number

2210212

By
Lina M. Khan, Former Chair and Commissioner;
Rebecca Kelly Slaughter, Former Commissioner;
Alvaro Bedoya, Former Commissioner
Related Releases
FTC Acts to Prevent Interlocking Directorate Arrangement, Anticompetitive Information Exchange in EQT, Quantum Energy Deal

Testimony of the Federal Trade Commission Before the House Committee on the Judiciary Concerning Oversight of the FTC

Before the House Committee on the Judiciary
Washington, D.C.
Congressional Session
117th Congress
Date
Matter Number

P210100

By
Lina M. Khan, Former Chair and Commissioner
Related Releases
FTC Provides Testimony Before the House Judiciary Committee at Oversight Hearing
Displaying 81 - 100 of 202

Join us at the FTC!

View our open positions

Return to top